ASTRAZENECA COMPLETES COMMERCIALISATION AGREEMENT WITH ASPEN FOR ANAESTHETICS PORTFOLIO 01 September 2016 07:00 BST ASTRAZENECA COMPLETES COMMERCIALISATION AGREEMENT WITH ASPEN FOR ANAESTHETICS PORTFOLIO AstraZeneca today announced that it has completed* the commercialisation agreement (https://www.astrazeneca.com/media-centre/press -releases/2016/astrazeneca-enters-commercialisation-agreement-with-aspen-for -anaesthetic-medicines-portfolio-08062016.html) with Aspen Global Incorporated (AGI), part of the Aspen Group, for rights to its global anaesthetics portfolio outside the US. The agreement covers seven established medicines - Diprivan (general anaesthesia), EMLA (topical anaesthetic) and five local anaesthetics (Xylocaine/Xylocard/Xyloproct, Marcaine, Naropin, Carbocaine and Citanest). As AstraZeneca will retain a significant ongoing interest in the portfolio, the upfront payment (to be recognised in the third quarter of 2016), along with all future milestone and royalty payments, will be reported as Externalisation Revenue in the Company’s financial statements. * With the exception of Ukraine and Zimbabwe, which are subject to separate closing About AstraZeneca AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com CONTACTS +------------------+-----------+------------------+ | Media Enquiries | | | +------------------+-----------+------------------+ | Neil Burrows | UK/Global | +44 203 749 5637 | +------------------+-----------+------------------+ | Vanessa Rhodes | UK/Global | +44 203 749 5736 | +------------------+-----------+------------------+ | Karen Birmingham | UK/Global | +44 203 749 5634 | +------------------+-----------+------------------+ | Rob Skelding | UK/Global | +44 203 749 5821 | +------------------+-----------+------------------+ | Jacob Lund | Sweden | +46 8 553 260 20 | +------------------+-----------+------------------+ | Michele Meixell | US | +1 302 885 2677 | +------------------+-----------+------------------+ +---------------------+-------------------------------------+------------------ -+ | Investor Relations | | | +---------------------+-------------------------------------+------------------ -+ | UK | | | +---------------------+-------------------------------------+------------------ -+ | Thomas Kudsk Larsen | | +44 203 749 5712 | +---------------------+-------------------------------------+------------------ -+ | Craig Marks | Finance, Fixed Income, M&A | +44 7881 615 764 | +---------------------+-------------------------------------+------------------ -+ | Nick Stone | Respiratory & Autoimmunity | +44 203 749 5716 | +---------------------+-------------------------------------+------------------ -+ | Henry Wheeler | Oncology | +44 203 749 5797 | +---------------------+-------------------------------------+------------------ -+ | Christer Gruvris | Infection & Neuroscience | +44 203 749 5711 | +---------------------+-------------------------------------+------------------ -+ | US | | | +---------------------+-------------------------------------+------------------ -+ | Lindsey Trickett | Cardiovascular & Metabolic Diseases | +1 240 543 7970 | +---------------------+-------------------------------------+------------------ -+ | Mitchell Chan | Oncology | +1 240 477 3771 | +---------------------+-------------------------------------+------------------ -+ | Toll-free | | +1 866 381 7277 | +---------------------+-------------------------------------+------------------ -+ -ENDS-
AstraZeneca Completes Aspen Agreement
| Quelle: AstraZeneca PLC
Anhänge
